Table 4.
The mean changes in clinical indicators from baseline at weeks 12 and 24 in both ACR50 and ACR70 negative groups and ACR50 and ACR70 positive groups
| ACR50 | ACR70 | ||||
|---|---|---|---|---|---|
| Negative | Positive | Negative | Positive | ||
| ΔDAS28 | W12 | 2.304 ± 1.626 | 2.688 ± 0.996 | 2.583 ± 1.257 | 2.51 ± 1.255 |
| W24 | 2.536 ± 1.598 | 2.857 ± 0.962 | 2.591 ± 1.314 | 2.898 ± 1.099 | |
| ΔMMP-3 | W12 | 84.914 ± 32.938 | 122.599 ± 149.654 | 102.92 ± 66.121 | 133.385 ± 182.232 |
| W24 | 69.139 ± 33.066 | 124.365 ± 107.828** | 76.244 ± 49.253 | 127.828 ± 220.685** | |
| ΔUS7 | W12 | 1.143 ± 1.215 | 9.154 ± 8.061*** | 1.75 ± 1.658 | 13.25 ± 7.704*** |
| W24 | 0.857 ± 1.676 | 9.692 ± 7.836*** | 1.5 ± 2.224 | 11.7 ± 7.775*** | |
| ΔCRP | W12 | 3.571 ± 4.315 | 8.769 ± 10.109 | 6.250 ± 7.689 | 8.000 ± 10.664 |
| W24 | 3.00 ± 5.888 | 7.385 ± 11.507 | 5.600 ± 9.582 | 6.100 ± 16.032 | |
| ΔAnti-CCP | W12 | 68.01 ± 166.238 | 69.32 ± 149.09 | 58.1 ± 143.488 | 72.145 ± 108.321 |
| W24 | 75.47 ± 158.87 | 77.35 ± 127.76 | 69.68 ± 122.58 | 77.65 ± 148.53 | |
| ΔHAQ | W12 | 8.429 ± 8.904 | 10.385 ± 13.556 | 7.33 ± 8.283 | 13.250 ± 15.926 |
| W24 | 9.429 ± 9.502 | 9.231 ± 8.757 | 8.0 ± 9.534 | 10.6 ± 8.235 | |
| ΔESR | W12 | 28.714 ± 22.134 | 31.615 ± 21.964 | 35.41 ± 20.291 | 32.75 ± 21.446 |
| W24 | 25.429 ± 19.68 | 22.231 ± 28.94 | 27.8 ± 20.065 | 18.90 ± 30.552 | |
The Δ symbol represents changes from baseline
ACR50 American College of Rheumatology 50% response, ACR70 ACR 70% response, CCP cyclic citrullinated peptide, CRP C-reactive protein, DAS28 disease activity score in 28 joints, ESR erythrocyte sedimentation rate, HAQ health assessment questionnaire, MMP-3 matrix metalloproteinase-3, US7 7-joint ultrasound score
Compared with the negative group, ***p < 0.001, **p < 0.01, *p < 0.05